We are live on ! Find out more
NMTR

9 Meters Biopharma
NMTR

Delisted

NMTR was delisted on the 25th of July, 2023.

Back to rankings

99 hedge funds and large institutions have $81.7M invested in 9 Meters Biopharma in 2021 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 14

36% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 25

10% more funds holding

Funds holding: 90 → 99 (+9)

8% less capital invested

Capital invested by funds: $88.6M → $81.7M (-$6.91M)

15% less call options, than puts

Call options by funds: $2.56M | Put options by funds: $3M

Holders
99
Holders Change
+9
Holders Change %
+10%
% of All Funds
1.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
34
Increased
31
Reduced
14
Closed
25
Calls
$2.56M
Puts
$3M
Net Calls
-$438K
Net Calls Change
+$185K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$11.9M
2
Deutsche Bank
Deutsche Bank
Germany
+$3.73M
3
State Street
State Street
Massachusetts
+$3.65M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.53M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.38M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$21.1M
2
TLP
Tri Locum Partners
New York
-$7.77M
3
CH
CVI Holdings
Delaware
-$2.5M
4
MWNA
Marshall Wace North America
New York
-$1.73M
5
Citigroup
Citigroup
New York
-$963K
Name Holding Trade Value Shares
Change 		Change in
Stake
X
76
Xponance
Pennsylvania
$13K +$14.3K +582 New
PSIWM
77
Paradigm Strategies in Wealth Management
Minnesota
$12K +$13.3K +540 New
OC
78
Oppenheimer & Co
New York
$12K +$13.4K +545 New
SCP
79
Sandhill Capital Partners
New York
$11K – – –
WS
80
Wedbush Securities
California
$11K – – –
CAN
81
Cetera Advisor Networks
California
$11K +$12.3K +500 New
GA
82
Gateway Advisory
New Jersey
$11K +$12.3K +500 New
IWM
83
IHT Wealth Management
Illinois
$11K +$12.3K +500 New
IFG
84
Independent Financial Group
California
$11K +$12.3K +500 New
PAG
85
Private Advisor Group
New Jersey
$11K +$12.3K +500 New
RF
86
Rollins Financial
Georgia
$11K +$12.3K +500 New
Wells Fargo
87
Wells Fargo
California
$8K -$2.28K -93 -20%
MA
88
MCF Advisors
Kentucky
$6K – – –
HI
89
Harbour Investments
Wisconsin
$6K +$6.51K +265 New
CG
90
Cutler Group
California
$4K -$7K -285 -59%
HFM
91
Hartford Financial Management
Connecticut
$4K – – –
PNC Financial Services Group
92
PNC Financial Services Group
Pennsylvania
$3K – – –
Fidelity Investments
93
Fidelity Investments
Massachusetts
$2K +$1.82K +74 +740%
CWP
94
Concord Wealth Partners
Virginia
$1K -$1.23K -50 -50%
TWA
95
TCI Wealth Advisors
Arizona
$1K -$1.23K -50 -59%
ASN
96
Advisory Services Network
Georgia
$1K +$614 +25 New
AIG
97
American International Group
New York
$131 +$146K +5,954 New
TLP
98
Tri Locum Partners
New York
– -$7.77M -332,217 Closed
CH
99
CVI Holdings
Delaware
– -$2.5M -106,723 Closed
MWNA
100
Marshall Wace North America
New York
– -$1.73M -73,998 Closed
1 2 3
4
5

NMTR Hedge Fund Activity: Q2 2021 in Review

99 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q2 2021, worth a combined $81.7M — down 7.8% from $88.6M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new NMTR positions and 25 closed out — a net gain of 9 holders — while 31 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $11.9M. The largest seller was OrbiMed, cutting an estimated $21.1M.

  • 99 institutional investors held 9 Meters Biopharma (NMTR) as of Q2 2021, up from 90 in Q1 2021.
  • Funds reported $81.7M of 9 Meters Biopharma stock for Q2 2021, down 7.8% quarter-over-quarter.
  • 34 funds opened new 9 Meters Biopharma positions in Q2 2021 and 25 closed out, a net change of +9 holders.
  • The largest 9 Meters Biopharma buyer in Q2 2021 was BlackRock, an estimated $11.9M added.
  • The largest 9 Meters Biopharma seller in Q2 2021 was OrbiMed, an estimated $21.1M sold.

Based on aggregated 13F filings for Q2 2021.